OX40

News

Sanofi gives up on amlitelimab in atopic dermatitis

Sanofi has stopped development of anti-OX40L drug amlitelimab in atopic dermatitis, a major blow to what was once viewed as a 'pipeline-in-a-product'.

News

Cancer risk scuppers Kyowa Kirin's autoimmune disease drug

Kyowa Kirin has terminated all clinical trials of its anti-OX40L antibody rocatinlimab, after cases of cancer were seen in patients taking the drug.

News

Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma

Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, despite mixed data in a phase 2 trial.

News

Key drug in Sanofi's $1.45bn Kymab buyout shows promise in e...

Already a major player in atopic dermatitis with Dupixent, Sanofi looked to expand its position in the category earlier this year when it

News

Amgen pays Kyowa $400m upfront for OX40 eczema drug

Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopi

Sanofi gives up on amlitelimab in atopic dermatitis

Cancer risk scuppers Kyowa Kirin's autoimmune disease drug

Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma

Key drug in Sanofi's $1.45bn Kymab buyout shows promise in e...

Amgen pays Kyowa $400m upfront for OX40 eczema drug

After failure in sickle cell, Fulcrum merges with Slate

Discover a new era of healthcare panel engagement: Grounded ...

OX40

Editor's Picks